newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra
Health

Alembic Pharmaceuticals announces USFDA Final Approval for Betamethasone Valerate Foam, 0.12%

Alembic Pharmaceuticals announces USFDA Final Approval for Betamethasone Valerate Foam, 0.12%

27 August 2024, Bengaluru: Alembic Pharmaceuticals Limited (Alembic) announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Betamethasone Valerate Foam, 0.12%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Luxiq Foam, 0.12%, of Norvium Bioscience, LLC (Norvium).

Betamethasone valerate foam, 0.12% is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp. Refer label for a detailed indication.

Alembic has a cumulative total of 213 ANDA approvals (185 final approvals and 28 tentative approvals) from USFDA.

Related posts

Torque Pharma Introduces its Newest Product under “Torque Refresh Hair Removal Cream”

Newsmantra

Piramal Pharma’s GHG Commitment Validated and Approved by SBTi

Newsmantra

Sitaram Jaipuria Foundation to honour lifesavers at the second Medical & Healthcare Excellence Awards

Newsmantra

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More